Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $23.67.

A number of research firms have commented on TVTX. Canaccord Genuity Group dropped their price objective on shares of Travere Therapeutics from $23.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, September 30th. Piper Sandler upped their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research note on Thursday, November 14th. Leerink Partners reiterated an "outperform" rating and issued a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday, October 8th. HC Wainwright cut their price target on Travere Therapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, September 27th. Finally, Wedbush boosted their price objective on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an "outperform" rating in a research note on Wednesday, October 9th.

Travere Therapeutics Stock Performance

Shares of TVTX traded up $0.04 during midday trading on Monday, reaching $17.32. 657,263 shares of the stock were exchanged, compared to its average volume of 1,385,066. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -3.81 and a beta of 0.69. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $20.33. The business's 50-day moving average price is $18.11 and its 200 day moving average price is $13.44.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.01. The company had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The firm's revenue was up 69.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.17) earnings per share. On average, sell-side analysts expect that Travere Therapeutics will post -3.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Travere Therapeutics news, CAO Sandra Calvin sold 12,090 shares of the firm's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at approximately $1,005,164.10. This trade represents a 18.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gary A. Lyons sold 40,000 shares of the company's stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $14.73, for a total transaction of $589,200.00. Following the completion of the sale, the director now directly owns 51,000 shares in the company, valued at $751,230. This trade represents a 43.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 67,090 shares of company stock worth $1,068,747 in the last quarter. Company insiders own 3.75% of the company's stock.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently bought and sold shares of TVTX. Creative Planning boosted its stake in shares of Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company's stock valued at $335,000 after acquiring an additional 995 shares during the last quarter. Forefront Analytics LLC lifted its holdings in Travere Therapeutics by 10.2% in the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company's stock valued at $109,000 after purchasing an additional 1,237 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of Travere Therapeutics by 3.8% during the 2nd quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company's stock worth $626,000 after purchasing an additional 2,774 shares during the last quarter. CWM LLC grew its holdings in shares of Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company's stock worth $70,000 after buying an additional 3,065 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Travere Therapeutics by 20.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company's stock valued at $279,000 after buying an additional 3,458 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.